Rakuten Medical, Inc. and LOTTE Biologics announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P....
Signs Agreement to Acquire K.F. (Cambodia) Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnin...
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-...
-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...
Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers New ...
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad populati...
Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, t...
Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business...
( This news story is developing.) The U.S.–India trade relationship entered dangerous new territory as former U.S. President Donald Trump an...
Novo Nordisk’s announcement of an executive reshuffle marks more than a routine leadership transition. It signals a strat...
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral t...
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company pioneering the development of site-specific and novel-format antibody-drug conjug...
Rob Truckenmiller, Senior Vice President, Head of US Vaccines, GSK, emphasized the importance of collaborative efforts and fi...
Exscientia plc (Nasdaq: EXAI), a frontrunner in AI-driven precision medicine, has officially announced a significant leadership adjustment and the submissi...
© 2026 Biopharma Boardroom. All Rights Reserved.
